Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II recombinant COVID-19 vaccine (Sf9 cells) trial in healthy adults and older adults
ChiCTR2000039994Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (16 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Geometric mean titer of anti-RBD specific antibody at 1 month after final vaccination and Adverse reactions within 7 days after each dose. Started Nov 2020; status: recruiting.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000039994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039994.